Nurix Therapeutics, Inc.
For the period ended Nov 30, 2025. Filed Jan 28, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jan 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(b) Director and Section 16 Officer Rule 10b5-1 Trading Arrangements
On November 10, 2025, Christine Ring, Chief Legal Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (Ring Plan), providing for the potential sale of up to 208,840 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Dr. Ring and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Dr. Ring. The shares will be sold at the times and prices specified in the Ring Plan. The Ring Plan expires on January 29, 2027, or upon the earlier completion of all authorized transactions thereunder.
No other director or Section 16 officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the quarter ended November 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.